Search

Your search keyword '"Wong, Ian Chi-Kei"' showing total 652 results
Start Over Author "Wong, Ian Chi-Kei"
652 results on '"Wong, Ian Chi-Kei"'

9. Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study

Author

Qin, Simon Xiwen, Cheng, Franco Wing Tak, Kwok, Wang Chun, Fung, Lydia W. Y., Ma, Tian Tian, Yiu, Hei Hang Edmund, Bloom, Chloe, McDonald, Christine F., Cheung, Ching-Lung, Lai, Francisco Tsz Tsun, Chui, Celine Sze Ling, Li, Xue, Wong, Carlos King Ho, Wan, Eric Yuk Fai, Wong, Ian Chi Kei, and Chan, Esther Wai Yin

Published
2024
Full Text
View/download PDF

10. Natural history of infants with vitamin D deficiency in Hong Kong

Author

Tung, Joanna Yuet-Ling, So, Hung-Kwan, Tung, Keith Tsz-Suen, Wong, Rosa Sze-Man, Tsang, Hing-Wai, Chan, Bianca, Tso, Winnie Wan-Yee, Wong, Ian Chi-Kei, Yam, Jason Cheuk-Sing, Lee, Samantha Lai-Ka, Pang, Gloria, Wong, Wilfred Hing-Sang, Cheung, Ka-Wang, Leung, Wing-Cheong, and Ip, Patrick

Published
2023

18. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong

Author

Lee, Sharen, Zhou, Jiandong, Leung, Keith Sai Kit, Wai, Abraham Ka Chung, Jeevaratnam, Kamalan, King, Emma, Liu, Tong, Wong, Wing Tak, Chang, Carlin, Wong, Ian Chi Kei, Cheung, Bernard Man Yung, Tse, Gary, and Zhang, Qingpeng

Published
2023
Full Text
View/download PDF

26. mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study

Author

Wan, Eric Yuk Fai, Chui, Celine Sze Ling, Mok, Anna Hoi Ying, Xu, Wanchun, Yan, Vincent Ka Chun, Lai, Francisco Tsz Tsun, Li, Xue, Wong, Carlos King Ho, Chan, Esther Wai Yin, Lui, David Tak Wai, Tan, Kathryn Choon Beng, Hung, Ivan Fan Ngai, Lam, Cindy Lo Kuen, Leung, Gabriel Matthew, and Wong, Ian Chi Kei

Published
2022
Full Text
View/download PDF

33. Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study

Author

Lai, Francisco Tsz Tsun, Yan, Vincent Ka Chun, Ye, Xuxiao, Ma, Tiantian, Qin, Xiwen, Chui, Celine Sze Ling, Li, Xue, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Cheung, Ching Lung, Li, Philip Hei, Cheung, Bernard Man Yung, Lau, Chak Sing, Wong, Ian Chi Kei, and Chan, Esther Wai Yin

Subjects
Comorbid patients -- Statistics -- Drug therapy, Health
Abstract

Background: Multimorbidity is a prevalent risk factor for COVID-19-related complications and death. We sought to evaluate the association of homologous booster vaccination using BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac) with COVID-19-related deaths among people with multimorbidity during the initial Omicron wave of the COVID-19 pandemic. Methods: Using routine clinical records from public health care facilities in Hong Kong, we conducted a territory-wide retrospective cohort study comparing people aged 18 years or older with 2 or more chronic conditions who received a homologous booster (third) dose with those who received only 2 doses, between Nov. 11, 2021, and Mar. 31, 2022. The primary outcome was death related to COVID-19. Results: We included 120 724 BNT162b2 recipients (including 87 289 who received a booster), followed for a median of 34 (interquartile range [IQR] 20-63) days and 127 318 CoronaVac recipients (including 94 977 who received a booster), followed for a median of 38 (IQR 22-77) days. Among BNT162b2 recipients, booster-vaccinated people had fewer COVID-19-related deaths than those who received 2 doses (5 v. 34, incidence rate 1.3 v. 23.4 per million person-days, weighted incidence rate ratio [IRR] 0.05, 95% confidence interval [CI] 0.02-0.16). We observed similar results among recipients of CoronaVac booster vaccination compared with those who received only 2 doses (26 v. 88, incidence rate 5.3 v. 53.1 per million person-days, weighted IRR 0.08, 95% CI 0.05-0.12). Interpretation: Among people with multimorbidity, booster vaccination with BNT162b2 or CoronaVac was associated with reductions of more than 90% in COVID-19-related mortality rates compared with only 2 doses. These results highlight the crucial role of booster vaccination for protecting vulnerable populations as the COVID-19 pandemic continues to evolve., Compared with the general population, people living with multimorbidity are disproportionately burdened by the ongoing COVID-19 pandemic. (1) Research shows a higher risk of SARS-CoV-2 infection (2) and death related [...]

Published
2023
Full Text
View/download PDF

37. Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study

Author

Chui, Celine Sze Ling, Fan, Min, Wan, Eric Yuk Fai, Leung, Miriam Tim Yin, Cheung, Edmund, Yan, Vincent Ka Chun, Gao, Le, Ghebremichael-Weldeselassie, Yonas, Man, Kenneth K.C., Lau, Kui Kai, Lam, Ivan Chun Hang, Lai, Francisco Tsz Tsun, Li, Xue, Wong, Carlos King Ho, Chan, Esther W., Cheung, Ching-Lung, Sing, Chor-Wing, Lee, Cheuk Kwong, Hung, Ivan Fan Ngai, Lau, Chak Sing, Chan, Joseph Yat Sun, Lee, Michael Kang-Yin, Mok, Vincent Chung Tong, Siu, Chung-Wah, Chan, Lot Sze Tao, Cheung, Terence, Chan, Frank Ling Fung, Leung, Anskar Yu-Hung, Cowling, Benjamin John, Leung, Gabriel Matthew, and Wong, Ian Chi Kei

Published
2022
Full Text
View/download PDF

44. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study

Author

Wan, Eric Yuk Fai, Chui, Celine Sze Ling, Wang, Yuan, Ng, Vanessa Wai Sei, Yan, Vincent Ka Chun, Lai, Francisco Tsz Tsun, Li, Xue, Wong, Carlos King Ho, Chan, Esther Wai Yin, Wong, Christina Sze Man, Leung, Kathy Sze Man, Ni, Michael Yuxuan, Valkenburg, Sophie Alessandra, Peiris, Joseph Sriyal Malik, Wu, Joseph Tsz Kei, Cowling, Benjamin John, Ashcroft, Darren M, Hung, Ivan Fan Ngai, Leung, Gabriel Matthew, and Wong, Ian Chi Kei

Published
2022
Full Text
View/download PDF

45. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.

Author

Lai, Francisco Tsz Tsun, Wang, Boyuan, Wei, Cuiling, Chui, Celine Sze Ling, Li, Xue, Cheung, Ching Lung, Wong, Ian Chi Kei, Chan, Esther Wai Yin, and Wan, Eric Yuk Fai

Subjects
MORTALITY prevention, PREVENTIVE medicine, COMBINATION drug therapy, RESEARCH funding, LOGISTIC regression analysis, PROBABILITY theory, GERIATRICS, ORAL drug administration, CAUSES of death, DESCRIPTIVE statistics, ANTIVIRAL agents, ODDS ratio, LONGITUDINAL method, DRUG efficacy, RITONAVIR, HOSPITAL care of older people, CONFIDENCE intervals, COVID-19, VACCINATION status, THERAPEUTICS, OLD age
Abstract

Background Molnupiravir and nirmatrelvir-ritonavir are orally administered pharmacotherapies for mild to moderate COVID-19. However, the effectiveness of these drugs among very old (≥80 years), hospitalised patients remains unclear, limiting the risk–benefit assessment of these antivirals in this specific group. This study investigates the effectiveness of these antivirals in reducing mortality among this group of hospitalised patients with COVID-19. Methods Using a territory-wide public healthcare database in Hong Kong, a target trial emulation study was conducted with data from 13 642 eligible participants for the molnupiravir trial and 9553 for the nirmatrelvir-ritonavir trial. The primary outcome was all-cause mortality. Immortal time and confounding bias was minimised using cloning-censoring-weighting approach. Mortality odds ratios were estimated by pooled logistic regression after adjusting confounding biases by stabilised inverse probability weights. Results Both molnupiravir (HR: 0.895, 95% CI: 0.826–0.970) and nirmatrelvir-ritonavir (HR: 0.804, 95% CI: 0.678–0.955) demonstrated moderate mortality risk reduction among oldest-old hospitalised patients. No significant interaction was observed between oral antiviral treatment and vaccination status. The 28-day risk of mortality was lower in initiators than non-initiators for both molnupiravir (risk difference: −1.09%, 95% CI: −2.29, 0.11) and nirmatrelvir-ritonavir (risk difference: −1.71%, 95% CI: −3.30, −0.16) trials. The effectiveness of these medications was observed regardless of the patients' prior vaccination status. Conclusions Molnupiravir and nirmatrelvir-ritonavir are moderately effective in reducing mortality risk among hospitalised oldest-old patients with COVID-19, regardless of their vaccination status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study

Author

Wan, Eric Yuk Fai, Chui, Celine Sze Ling, Lai, Francisco Tsz Tsun, Chan, Esther Wai Yin, Li, Xue, Yan, Vincent Ka Chun, Gao, Le, Yu, Qiuyan, Lam, Ivan Chun Hang, Chun, Raccoon Ka Cheong, Cowling, Benjamin John, Fong, Wing Chi, Lau, Alexander Yuk Lun, Mok, Vincent Chung Tong, Chan, Frank Ling Fung, Lee, Cheuk Kwong, Chan, Lot Sze Tao, Lo, Dawin, Lau, Kui Kai, Hung, Ivan Fan Ngai, Leung, Gabriel Matthew, and Wong, Ian Chi Kei

Published
2022
Full Text
View/download PDF

48. Development and validation of risk prediction model for recurrent cardiovascular events among Chinese: the Personalized CARdiovascular DIsease risk Assessment for Chinese model

Author

Zhou, Yekai, primary, Lin, Celia Jiaxi, additional, Yu, Qiuyan, additional, Blais, Joseph Edgar, additional, Wan, Eric Yuk Fai, additional, Lee, Marco, additional, Wong, Emmanuel, additional, Siu, David Chung-Wah, additional, Wong, Vincent, additional, Chan, Esther Wai Yin, additional, Lam, Tak-Wah, additional, Chui, William, additional, Wong, Ian Chi Kei, additional, Luo, Ruibang, additional, and Chui, Celine Sze Ling, additional

Published
2024
Full Text
View/download PDF

49. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease

Author

Mak, Lung-Yi, primary, Chung, Matthew Shing Hin, additional, Li, Xue, additional, Lai, Francisco Tsz Tsun, additional, Wan, Eric Yuk Fai, additional, Chui, Celine Sze Ling, additional, Cheng, Franco Wing Tak, additional, Chan, Esther Wai Yin, additional, Cheung, Ching Lung, additional, Au, Ivan Chi Ho, additional, Xiong, Xi, additional, Seto, Wai-Kay, additional, Yuen, Man-Fung, additional, Wong, Carlos King Ho, additional, and Wong, Ian Chi Kei, additional

Published
2024
Full Text
View/download PDF

50. Evaluating different low‐density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study

Author

Wan, Eric Yuk Fai, primary, Xu, Wanchun, additional, Mok, Anna Hoi Ying, additional, Chin, Weng Yee, additional, Yu, Esther Yee Tak, additional, Chui, Celine Sze Ling, additional, Chan, Esther Wai Yin, additional, Wong, Ian Chi Kei, additional, Lam, Cindy Lo Kuen, additional, and Danaei, Goodarz, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results